Insecticides (India) Limited — Investor Meet, 04-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

IIL's Q3 & 9M FY26 earnings call highlighted 8% Q3 revenue growth, volume-led by B2B, despite challenging conditions. 9M revenue rose 4% to INR 1,714 Cr, gross profit up 7% to INR 546 Cr; EBITDA and PAT were flat. New products gained traction. Q4 margins face pressure, but management expects FY27 recovery with 8-10% growth via specialty products, capacity expansion (Dahej, Sotanala), and premiumization. High sales returns (INR 200 Cr) impacted finance costs. Outlook: cautious near-term, confident long-term.